ZACHARY SHEPPARD: Open Payments
NPI 1205244753 · SPRING, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,835 in 72 payments from 17 companies in 2025. Trend: 2023 $209 · 2024 $1,784 · 2025 $1,835
Food & beverage: $1,835
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 20 | $628 |
| Amgen Inc. | 11 | $375 |
| AstraZeneca Pharmaceuticals LP | 10 | $214 |
| GlaxoSmithKline, LLC. | 10 | $184 |
| ABBVIE INC. | 3 | $68 |
| Exact Sciences Corporation | 3 | $58 |
| Kowa Pharmaceuticals America, Inc. | 3 | $49 |
| Corcept Therapeutics | 2 | $40 |
| Abbott Laboratories | 2 | $39 |
| KYOWA KIRIN, INC. | 1 | $29 |
Products named: Wegovy, REPATHA, AIRSUPRA, TRELEGY ELLIPTA, FARXIGA, SHINGRIX, Rybelsus, Ozempic.
Industry payments across TX — which companies pay providers there.
